Prognostic comparison of lymph node metastasis subtypes in lung adenocarcinoma: clinical implications of intranodal metastasis versus extranodal extension for optimizing R classification [0.03%]
肺腺癌淋巴结转移亚型的预后比较：淋巴结内转移与淋巴结外侵犯的临床意义及优化R分类
Jia-Yong Wu,Guo-Zhong Liang,Tian-Qing Chen et al.
Jia-Yong Wu et al.
Background: Lung adenocarcinoma (LUAD) prognosis is strongly influenced by lymph node (LN) status. While extranodal extension (ENE) is a recognized negative prognostic factor, the International Association for the Study o...
Reply to letter to the editor "The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non-Small-Cell lung cancer" [0.03%]
来信“派姆单抗联合或不联合培美曲塞作为晚期非鳞状非小细胞肺癌诱导治疗后的维持治疗的有效性”的回信
Bas J M Peters,Stefan Böhringer,Esmee van Geffen
Bas J M Peters
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer [0.03%]
关于Durvalumab联合化疗并联用或不联用Oleclumab治疗初治的转移性非小细胞肺癌（NSCLC）患者的Ⅲ期研究（MAGELLAN arms B1和B3）
Byoung Chul Cho,Chaiyut Charoentum,Dong-Wan Kim et al.
Byoung Chul Cho et al.
Objectives: Standard-of-care therapies for metastatic non-small-cell lung cancer (mNSCLC) have mixed outcomes that remain unsatisfactory. Durvalumab (anti-PD-L1) plus oleclumab (anti-CD73) might provide a synergistic anti...
Informed choice for lung cancer screening: A randomised trial of three decision support tools [0.03%]
有关肺癌筛查的知情选择：三种决策支持工具的随机试验
Rachael H Dodd,Marianne Weber,Kathleen McFadden et al.
Rachael H Dodd et al.
Shared decision-making in the Australian National Lung Cancer Screening Program (NLCSP) involves consultation between healthcare provider and individual to ensure participants make an informed choice about screening. Three decision support ...
Treatment response after induction therapy in advanced thymic tumors: results from the Italian nationwide TYME database [0.03%]
意大利全国TYME数据库中诱导治疗后晚期胸腺肿瘤的治疗反应结果分析
Giovanni Leuzzi,Federica Sabia,Claudia Proto et al.
Giovanni Leuzzi et al.
Background: Induction therapy (IT) prior to surgery is a key strategy to improve resectability in advanced thymic tumors (ATTs). This study aimed to assess prognostic factors and the impact of IT on clinical outcomes. ...
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS [0.03%]
关于Tarlatamab给药及管理CRS/ICANS的多机构观点
Bingnan Zhang,Laura Alder,Samuel Rosner et al.
Bingnan Zhang et al.
Background: Tarlatamab, a bispecific T-cell engager, is the first treatment in many years to significantly improve overall survival in relapsed extensive stage small cell lung cancer (ES-SCLC). However, implementation of ...
Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis [0.03%]
程序性死亡配体1对表皮生长因子受体突变型非小细胞肺癌一线奥希替尼疗效的影响：AURORA研究（研究编号25）的真实世界数据和荟萃分析结果
Marliese Alexander,Malinda Itchins,Jonathan Felthun et al.
Marliese Alexander et al.
Introduction: The prognostic significance of PD-L1 expression in EGFR-mutant non-small cell lung cancer (NSCLC) treated with first-line osimertinib remains uncertain. This study evaluated its association with survival in ...
Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study [0.03%]
亚洲表皮生长因子受体突变阳性局部晚期或转移性非小细胞肺癌患者一线使用达可替尼治疗的现实世界应用和临床结局：ARIA研究最终分析结果
Lin Wu,Junling Li,Chong-Rui Xu et al.
Lin Wu et al.
Background: Dacomitinib, a second-generation, irreversible tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), showed statistically significant progression-free survival improvement over gefitinib in pat...
Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis [0.03%]
PD-1/PD-L1抑制剂联合以铂类为基础的化疗与单纯化疗对比治疗局部晚期或转移性肺淋巴上皮瘤样癌的长期生存分析：更新随访分析
Yanna Tang,Wei Du,Xuanye Zhang et al.
Yanna Tang et al.
Purpose: Pulmonary lymphoepithelioma-like carcinoma (PLELC), a rare Epstein-Barr virus (EBV)-associated non-small-cell lung cancer (NSCLC) subtype, exhibits distinct clinicopathological features but lacks evidence-based f...
Radiotherapy outcomes in patients with interstitial lung disease and interstitial lung abnormalities: Adverse events and survival from a UK tertiary centre [0.03%]
英国三级医疗中心间质性肺病和间质性肺异常患者的放疗结果：不良事件及生存率
Sarah Bowen Jones,Conal Hayton,Ahmed Lodhi et al.
Sarah Bowen Jones et al.
Background: Interstitial lung disease (ILD) encompasses a spectrum of inflammatory and fibrotic lung conditions. Interstitial lung abnormalities (ILA) are incidental radiological findings with the potential to progress to...